Brainstorm Cell Therapeutics, Inc. (BCLI)
1.168
+0.10
(+9.62%)
USD |
OTCM |
Sep 01, 16:00
Brainstorm Cell Therapeutics Cash from Investing (Quarterly) : 0.00 for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.012M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.196M |
| September 30, 2023 | -0.012M |
| June 30, 2023 | 0.004M |
| March 31, 2023 | 2.005M |
| December 31, 2022 | 1.038M |
| September 30, 2022 | -0.011M |
| June 30, 2022 | -0.012M |
| March 31, 2022 | -0.017M |
| December 31, 2021 | -1.297M |
| September 30, 2021 | 1.696M |
| June 30, 2021 | -0.039M |
| March 31, 2021 | -0.037M |
| December 31, 2020 | -0.302M |
| September 30, 2020 | -0.086M |
| June 30, 2020 | -2.07M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.994M |
| December 31, 2019 | -0.345M |
| September 30, 2019 | 1.439M |
| June 30, 2019 | 1.391M |
| March 31, 2019 | 3.131M |
| December 31, 2018 | 3.968M |
| September 30, 2018 | 4.983M |
| June 30, 2018 | -13.03M |
| March 31, 2018 | 2.864M |
| December 31, 2017 | 2.745M |
| September 30, 2017 | -7.238M |
| June 30, 2017 | 6.78M |
| March 31, 2017 | 1.699M |
| December 31, 2016 | 0.788M |
| September 30, 2016 | 0.286M |
| June 30, 2016 | 0.137M |
| March 31, 2016 | 4.766M |
| December 31, 2015 | 0.898M |
| September 30, 2015 | 1.939M |
| June 30, 2015 | -0.555M |
| March 31, 2015 | -13.56M |
| December 31, 2014 | -2.757M |
| September 30, 2014 | -1.606M |
| June 30, 2014 | -0.002M |
| March 31, 2014 | -0.085M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| NovelStem International Corp. | 0.00 |
| Summit Therapeutics, Inc. | 222.41M |
| Kezar Life Sciences, Inc. | 1.529M |
| Protara Therapeutics, Inc. | 17.75M |
| Clene, Inc. | -0.001M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.895M |
| Cash from Financing (Quarterly) | 0.898M |
| Free Cash Flow | -4.057M |
| Free Cash Flow Per Share (Quarterly) | -0.0811 |
| Free Cash Flow to Equity (Quarterly) | -0.781M |
| Free Cash Flow to Firm (Quarterly) | -0.653M |
| Free Cash Flow Yield | -31.51% |